In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ashley Yeo

Ashley Yeo is attached to the medtech titles within Informa’s Pharma intelligence division.

As Health Care editor on In Vivo (monthly hardcopy and online daily services), he writes and commissions news and feature material to meet the strategic business and market access information needs of senior players and device makers as they move innovations into the global medtech market place.

As part of the Principal Analyst team, he also contributes news delivery and insight needs across the group’s other medtech titles in the field of market access (global regulatory, reimbursement, policy changes). Key areas of focus are Germany, the UK and global themes, and EU and other outside global regulatory insight.

A linguist by training, he joined what was later to become Informa in mid-1988 as a French and German news reporter (with some other European languages also in the mix), and has been editor of three of the group’s titles (including Clinica) over a 14-year-period.

These duties are combined with supporting the growing Ask The Analyst service. He says: “This helps us as a group keep a close relationship with long-term and potential subscribers in a sector where insight and knowledge are key to our clients’ commercial success.”

Latest From Ashley Yeo

Biosecurity Centre And ‘Test And Trace’ To Augment UK’s COVID-19 Test Momentum

The UK has added important new capabilities to its COVID-19 monitoring and control effort and those running it promise a “world class system” by late summer.

United Kingdom Policy

Fact File: European COVID-19 Focus Shifts To Managing The ‘New Normal’

The evolution of how and where patients receive their care has received an unexpected boost from the COVID-19 crisis. Coronavirus volume testing challenges persist, but the global medtech industry is now looking beyond the crisis toward a return to “normal” business.

Coronavirus COVID-19 Business Strategies

Change Is Coming In Health Care, If Not Yet At The Speeds Of Other Consumer Industries

The advent of COVID-19 and its effects on care delivery have meant that short-term priorities for health care systems have switched temporarily to public health emergency mode. But the longer-term need to restructure delivery around outcomes and federated data management for patients is here to stay, says Royal Philips’ Jeroen Tas.

Business Strategies Commercial

Philips Augments HealthSuite With New Clinical Trials Offering

Philips has added a Clinical Trials Accelerator functionality to the cloud-based HealthSuite digital platform, underlining its role in securely managing and collecting device and personal data for use by third-party clients seeking to build health care solutions.

Commercial Clinical Trials

South Korea Implements IVD Regulation Amid Renewed COVID-19 Scare

South Korea, one of the first countries to be hit by the spread of COVID-19 from China, has implemented new standalone IVD regulations.

South Korea Coronavirus COVID-19

UK Devices Bill Back On The Agenda As Govt Tries To Get COVID-19 Crisis Under Control

Post-Brexit planning is now fully back on the agenda in the UK, and work to shape its post-EU medtech regulatory future is also restarting.

United Kingdom Regulation
See All
UsernamePublicRestriction

Register